Medical News

RSS

Roche RTS Protein Expression portfolio transferred to RiNA GmbH

Roche and RiNA GmbH of Berlin have agreed to transfer the complete Roche Applied Science RTS Protein Expression portfolio to RiNA GmbH, effective September 15, 2009.

8 Sep 2009

Preliminary results of Phase III Gvhd trials announced by Osiris Therapeutics

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). GvHD, the most common complication of bone marrow transplantation, is a life-threatening disease for which there is currently no approved treatment. Prochymal showed significant improvements in response rates in difficult-to-treat liver and gastrointestinal GvHD, however neither trial reached its primary endpoint.

8 Sep 2009

Haemonetics acquires SEBRA's blood collection and processing business

Haemonetics Corporation, a global blood management solutions company, and Engineering and Research Associates Inc. (known as "SEBRA(R)"), a leading provider of blood and medical manufacturing technologies, announced today that Haemonetics has acquired the assets of SEBRA's blood collection and processing business for $12.5 million cash. The acquisition is expected to close within the next several weeks.

8 Sep 2009

Largest first responder purchase of Masimo Rad-57 Pulse CO-Oximeters made by the Fire Department of NY

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced that the Fire Department of New York City (FDNY) has purchased 86 Masimo Rad-57 Pulse CO-Oximeters as part of their strategic initiative to "improve the survivability of firefighters and victims suffering from carbon monoxide (CO) toxicity."

8 Sep 2009

Pharos Innovations' RPM technology enables healthcare cost reduction

Pharos Innovations announced today that results of the Henry Ford Health System Patient-Centered Team Care program show a 36% reduction in expected all-cause hospital admissions for enrolled heart failure patients after six months of enrollment and a return of 2.3:1 vs. program costs.

8 Sep 2009

Western Dental Services launches digital X-ray imaging program

CDW Healthcare, part of the public sector subsidiary of CDW Corporation and a leading provider of technology products and services to healthcare organizations, today announced that Western Dental Services, Inc. (“Western Dental”) of Orange, Calif., launched an extensive digital X-ray imaging program powered via technology configured and deployed by CDW Healthcare.

8 Sep 2009

eBioscience Corporation announces the acquisition of NatuTec GmbH

eBioscience Corporation, a leading global provider of innovative, high-quality cell analysis reagents announced today the acquisition of NatuTec GmbH, a leading distributor of high-quality biological research reagents located in Frankfurt am Main, Germany.

8 Sep 2009

Exposure to air pollution can cause heart attack

It's well known that measures such as exercise, a healthy diet and not smoking can help reduce high blood pressure, but researchers at the University of Michigan Health System have determined the very air we breathe can be an invisible catalyst to heart disease.

8 Sep 2009

FDA undecided on safety guidelines for hydroquinone use

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the US market for physician-dispensed cosmeceutical pigment control products will experience considerable growth in sales over the next five years. MRG's US Markets for Physician-Dispensed Cosmeceuticals 2009 report finds, however, that product safety issues involving hydroquinone, the active ingredient in many pigment control products, have led the Food and Drug Administration (FDA) to second guess the use of the compound in such products.

8 Sep 2009

Valentx raises funds to develop less-invasive treatment for morbid obesity

ValenTx, Inc., announced today the closing of a $22 million Series B Preferred Stock financing. The round was led by SV Life Sciences and joined by Covidien Ventures, as well as all the Company’s existing venture capital investors: Sapient Capital, EDF Ventures, Kaiser Permanente Ventures, Affinity Capital Partners, and TGap Ventures.

8 Sep 2009

Powered SAFE Scribe hair replacement technique unveiled at ISHRS meeting

James A. Harris, M.D., director of Hair Sciences Center of Colorado, which specializes in state-of-the-art medical and surgical hair restoration, recently introduced to surgeons around the world his latest advancement in hair replacement, the Powered SAFE Scribe. The product was unveiled to the medical community during the 17th Annual Scientific Meeting of the International Society of Hair Restoration Surgery (ISHRS) held in late July in Amsterdam.

8 Sep 2009

Lab Research announces the signing of three new master services agreements with global companies

LAB Research Inc. ("LAB", "LAB Research" or the "Company"), (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced that it has entered into three new master services agreements with some of the most important global sponsors for each of the pharmaceutical, biotechnology and agro-chemical industries.

8 Sep 2009

New data fuels disagreements over regional Medicare spending

New data fuels some regional disputes on Medicare spending while some communities create better care and spend less than others. The New York Times reports that "new government data show that Medicare costs per patient in those cities [New York City, Boston] are slightly below the national average when the numbers are adjusted for the cost of living and other factors.

8 Sep 2009

Opexa Therapeutics' ongoing development program for Tovaxin to be presented

Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s president and chief executive officer, will deliver a corporate presentation at Rodman & Renshaw’s 11th Annual Healthcare Conference.

8 Sep 2009

Rosetta Genomics and AXA Diagnostics sign exclusive distribution agreement

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, and AXA Diagnostics, a privately owned company that markets specialized diagnostic tests, announced today the signing of an exclusive distribution agreement in Italy for Rosetta Genomics’ three currently available diagnostic tests.

8 Sep 2009

EDS signs $8.1 million contract with U.S. DoD Military Health System

EDS, an HP company, today announced it has signed an $8.1 million, 12-month add-on contract with the U.S. Department of Defense (DoD) Military Health System to make technical enhancements to several Defense Health Information Management Systems (DHIMS).

8 Sep 2009

Research to develop new techniques for studying wild and transgenic mice's nervous system

Researchers of the Pablo de Olavide University (Seville) have started different projects based on the study of phenotype techniques in mice and their applicability to the pharmaceutical industry and neurodegenerative medicine.

8 Sep 2009

RIKEN Yokohama Institute to purchase Genetic Analysis Systems from Helicos BioSciences

Helicos BioSciences Corporation (NASDAQ:HLCS) today announced that the RIKEN Yokohama Institute Omics Science Center (OSC) has agreed to purchase four Helicos™ Genetic Analysis Systems. The transaction represents the first multisystem sale of the Helicos system to a large genome center. Shipments are expected to take place in September, with one system remaining in Cambridge to be used in a scientific collaboration between the two parties that began last year.

8 Sep 2009

New book on weight loss and fitness released

Modern American society is filled with easily accessible fatty foods, a growing obesity epidemic and a general lack of healthy living. In his new book, "Lose Weight, Feel Great: How I Lost Over 60lbs. with the Help of a Personal Trainer" (published by AuthorHouse), author Kevin Given tells of his personal struggles with obesity, how he lost over 60 pounds with the help of a personal trainer, and how others can change their lifestyles and bodies as well.

8 Sep 2009

Protalix receives orphan drug designation for prGCD

Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that the FDA’s Office of Orphan Products Development has granted orphan drug designation to prGCD, the Company’s proprietary plant cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.

8 Sep 2009